
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
Published on 16 June 2023
BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development

BI-1910 is now the second of the company's anti-tumour necrosis factor receptor 2 programmes to enter clinical development